Quest Diagnostics (DGX) risk factors, FY2024 10-K

RISKS RELATED TO OUR BUSINESS

1. 01The U.S. healthcare system continues to evolve, and medical laboratory testing market fundamentals are changing, and our business could be adversely impacted if we fail to adapt
2. 02The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability
3. 03Government payers, such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical testing services
4. 04Reimbursement for Medicare services also is subject to annual reduction under the Budget Control Act of 2011, and the Statutory Pay-As-You-Go Act of 2010
5. 05Health plans and other third parties have taken steps to reduce the utilization and reimbursement of health services, including clinical testing services
6. 06payment and requiring preauthorization of certain testing. There are also an increasing number of patients enrolling in consumer driven products and high deductible plans that involve greater patient cost-sharing
7. 07Failure to develop, acquire licenses for, introduce, or commercialize new tests, technology and services could negatively impact our testing volume, revenues and profitability
8. 08Failure to establish, and perform to, appropriate quality standards, or to assure that the appropriate standard of quality is observed in the performance of our diagnostic information services, could adversely affect the results of our operations and adversely impact our reputation

RISKS RELATED TO CHANGE IN PUBLIC POLICY

1. 09operating results. The potential impact of new policies that may be implemented as a result of the new administration is currently uncertain
2. 10We are subject to numerous legal and regulatory requirements governing our activities, and we may face substantial fines and penalties, and our business activities may be impacted, if we fail to comply
3. 11Our business and operations could be adversely impacted by the FDA's approach to regulation
4. 12Failure to accurately bill for our services, or to comply with applicable laws relating to billing government healthcare programs, could have a material adverse effect on our business
5. 13We are subject to numerous political (including geopolitical), legal, operational and other risks as a result of our international operations which could impact our business in many ways
6. 14We may be unable to obtain, maintain or enforce our intellectual property rights and may be subject to intellectual property litigation that could adversely impact our business
7. 15Adverse results in material litigation could have an adverse financial impact and an adverse impact on our client base and reputation

RISKS RELATED TO OUR INDEBTEDNESS

1. 16Our outstanding debt may impair our financial and operating flexibility

RISKS RELATED TO OUR OPERATIONS

1. 17We have been and expect to continue to use AI technology in the testing services we offer. The challenges with properly managing the development and use of these technological innovations could result in harm to our reputation, business or customers, and adversely affect our results of operations
2. 18Our business could be negatively affected if we are unable to continue to strengthen our efficiency
3. 19Our business operations and reputation may be materially impaired if we do not comply with privacy laws or information security policies
4. 20Our approach to corporate responsibility may not satisfy all our stakeholders
5. 21The IT systems that we rely on may be subject to unauthorized tampering, cyberattack or other security breach
6. 22Our ability to attract and retain qualified employees and maintain good relations with our employees is critical to the success of our business and the failure to do so may materially adversely affect our performance
7. 23Business development activities are inherently risky and integrating our operations with businesses we acquire may be difficult
8. 24Our operations may be adversely impacted by the effects of natural disasters such as hurricanes and earthquakes, public health emergencies and pandemics, geopolitical matters, hostilities or acts of terrorism and other criminal activities
9. 25Any future public health emergencies or pandemics may negatively affect us, including through its impact on the labor force and supply chain
10. 26Inflationary pressures could adversely impact us because of increases in the costs of materials, supplies and services, and increased labor and people-related expenses
11. 27CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
12. 28(d) Impact of changes in payment mix, including increased patient financial responsibility and any shift from fee-for-service to discounted, risk-sharing, capitated or bundled fee arrangements
13. 29(4) the impact of increased prior authorization programs
14. 30(i) Denial, suspension or revocation of CLIA certification or other licenses for any of our clinical laboratories under the CLIA standards, revocation or suspension of the right to bill the Medicare and Medicaid programs or other adverse regulatory actions by federal, state and local agencies
15. 31(n) Failure of the Company to maintain, defend and secure its financial, accounting, technology, customer data and other operational systems from cyberattacks, IT system outages, telecommunications failures, malicious human acts and failure of the systems of third parties upon which the Company relies
16. 32(p) Challenges with properly managing the development and use of AI
17. 33(2) inability to obtain or maintain adequate patent or other proprietary rights for our products and services or to successfully enforce our proprietary rights
18. 34(t) The complexity of billing and revenue recognition for clinical laboratory testing
19. 35(v) Inability to hire or retain qualified employees, including key senior management personnel, and maintain good relations with our employees
20. 36(x) Difficulties and uncertainties in the discovery, development, regulatory environment and/or marketing of new services or solutions or new uses of existing tests
21. 37(dd) Any future public health emergency or pandemic